Obesity – Kailera K9531-3107

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

Key Inclusion Criteria:

• BMI ≥35 kilograms per square meter (kg/m^2).
• History of at least 1 self-reported unsuccessful effort to lose weight with diet and exercise within the prior 6 months.
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.